Examiner Cite

No

1 5817087

Initial*

Name of Patentee or Applicant

of cited Document

Takabayashi et al.

Remove

Add

Add Remove

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

PTO/SBIDS+ (D1-10)

X

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Patent Number

	Application Number		10764589
	Filing Date		2004-01-27
	First Named Inventor Taka		aki Shimada
	Art Unit		3761
	Examiner Name	Melar	ie Jo HAND
	Attorney Docket Number		2038-323

U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite I	No Publication Number			ation	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
If you wie	1 h to a	ki additional IIS Pub	ished Ar	nlication	citation	a information please eliek the Ad-		d butte	on Add	
ii jou iiio	If you wish to add additional U.S. Published Application citation information please click the Add button. Add FOREIGN PATENT DOCUMENTS Remove									
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TA
	1	0761193	EP			1996-08-01				×

1999.10.04

NON-PATENT LITERATURE DOCUMENTS

U.S. PATENTS

Code¹ Issue Date

If you wish to add additional U.S. Patent citation information please click the Add button.

FP

If you wish to add additional Foreign Patent Document citation information please click the Add button

1998-10-06

0990434

	Application Number		10764589	
	Filing Date		2004-01-27	
INFORMATION DISCLOSURE	First Named Inventor Takas		aki Shimada	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		3761	
(Not for Submission under or or it 1.50)	Examiner Name	Melar	nie Jo HAND	
	Attorney Docket Numb	er	2038-323	

Initials*	No	(book, magazine, journal, senal, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	l»	
	1	European Search Report for Application No. 04704758.4 mailed September 1, 2011	×	

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line th							
citation if not in confo	rmance and not considered. Include conv of this form with	next communication	to applicant.				

"EXAMINET: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 See Krid Codes of UBPTO Patient Documents all princt USETIO_GODY or MPEP 801.84. "Entire office that issued the document, by the involvation code of USETIO Patient Documents. The includes on the page of the improve must previous the sense in united of the patient concent.

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10764589			
	Filing Date			2004-01-27		
	First Named Inventor	Takaa	aki Shimada			
	Art Unit			3761		
	Examiner Name	Melar	ie Jo HAND			
	Attorney Docket Number		2038-323			

29310

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 FR 1976(41).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CPR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CPR 1/37(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

Benjamin J. Hauptman

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

	form of the signature.	•		
	Signature	/Benjamin J. Hauptman/	Date (YYYY-MM-DD)	2011-11-30

Registration Number

This collection of information is required by 3T CRR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 3T CRR 1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Operatment of Commence, P. 0. Dax 1436, Alexandris, V.S. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, V.S. 2231-1450.

Name/Print

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbrary, and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested more considerable or the patient of the patient of

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.